A Problematic Biomarker Trial Design.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34289052.
- Also identified by DOI 10.1093/jnci/djab144 and PMC identifier 8826527.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Efficient biomarker-driven randomized clinical trials are a key tool for implementing precision oncology. A commonly used biomarker phase III design is focused on testing the treatment effect in biomarker-positive and overall study populations. This approach may result in recommending new treatments to biomarker-negative patients when these treatments have no benefit for these patients.
Medical subject headings
- Neoplasms
- Research Design